Lilly's $3.8 Billion Vaccine Bets: A Quiet Shift Now
Lilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
A practical intro to yield programs for USDC, focusing on how to earn with confidence and manage associated risks. Learn the basics and start optimizing today.
12,846 articlesLilly's heavy reliance on GLP-1 drugs has investors watching as the company bets $3.8B on vaccines. This analysis exp...
As market volatility rattles mid-year trading, a growing cohort of traders is turning to funded trading accounts. Thi...
CNM's first-quarter numbers set the stage for the year ahead. This guide breaks down what the earnings mean for inves...
Medicare Part B premiums rose to $202.90 per month in 2026, a 9.7% jump that tightens budgets for retirees. Here’s wh...
A fresh health-economics study links the use of GLP-1 obesity drugs to sizable lifetime medical cost reductions for 4...
Archer Aviation advances toward FAA Type Certification, with a looming Texas governance vote and a quarterly report t...
A decades‑long pause in U.S. nuclear construction has reshaped the investment landscape, rewarding a utility with a l...
Banking offers for new checking accounts are surging in mid-2026 as lenders chase deposits. This guide explains how t...
Medicare's first round of drug-price negotiations slashes list prices on 10 widely used drugs by up to 79% starting J...
A new bipartisan housing bill aims to curb investor hoarding and expand aid for first-time buyers. The measure would ...
A late-stage setback for Jazz Pharmaceuticals' lung cancer drug Zepzelca rattled investors, but the larger story may ...
A renewed push to replenish and expand U.S. missile arsenals is set to lift production and backlog across defense sup...